Spectral AI Announces 2025 Third Quarter Financial Results

Rhea-AI Summary

Spectral AI (NASDAQ: MDAI) reported third-quarter 2025 results for the period ended September 30, 2025, highlighting Q3 R&D revenue of $3.8 million and YTD revenue of $15.6 million. Cash improved to $10.5 million as of Sept 30, 2025 (flat vs Q2 2025; up from $3.7M in Q3 2024). The company recorded a Q3 net loss of $3.6 million versus $1.5 million a year earlier, driven by a 54% decline in R&D revenue after its June De Novo submission to the FDA.

After quarter close (Oct 22, 2025) Spectral entered a securities purchase agreement raising ~$7.6 million gross via common shares, warrants and pre-funded warrants. Full-year revenue guidance was lowered from $21.5M to $18.5M, citing BARDA timing and a U.S. government shutdown impact.

Positive

• Cash balance of $10.5M as of Sept 30, 2025
• Raised approximately $7.6M in Offering and Private Placement (Oct 22, 2025)
• YTD revenue of $15.6M for 2025

Negative

• Research & Development revenue declined 54% to $3.8M in Q3 2025
• Net loss widened to $3.6M in Q3 2025 from $1.5M in Q3 2024
• FY2025 revenue guidance reduced from $21.5M to $18.5M

Insights

Financial Analyst

Spectral AI shows stronger liquidity but weaker revenue and wider losses; progress toward FDA De Novo and a post‑quarter financing temper near‑term concerns.

The company recorded $3.8 million in Q3 research and development revenue, down 54%, and a Q3 net loss of $(3.6) million; gross margin was 42.7% and cash stood at $10.5 million. Management reduced FY 2025 revenue guidance from $21.5 million to $18.5 million, citing BARDA timing and a US government shutdown effect.

Liquidity improved via about $2.5 million from option/warrant exercises and a post‑period financing that raised approximately $7.6 million through an Offering and Private Placement; financials presented exclude that amount. The company continues progress toward an FDA De Novo submission and plans commercialization of the DeepView™ System.

Key dependencies and risks include the pace of De Novo regulatory progress, timing and deliverables under the BARDA PBS Contract, and realization of proceeds from the October 22, 2025 financing; these factors drive whether reduced 2025 revenue recovers in 2026. Monitor three near‑term items: the integration of the $7.6 million proceeds into the balance sheet, updates on the FDA De Novo pathway, and any BARDA milestone timing changes over the next 6–12 months.

Q3 Overview

• Research & Development Revenue of $3.8 Million; $15.6 Million in YTD Revenue for 2025
• Strong Cash position of $10.5 Million and progress toward FDA De Novo submission

DALLAS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the third quarter ended September 30, 2025 and provided an update on its ongoing business activities. The Company maintained a strong cash position of $10.5 million, recorded $3.8 million in research and development revenue, and continued to advance key regulatory and operational milestones, including progress toward its De Novo FDA submission.

“Spectral AI continues to maintain operational efficiency and strengthen our cash reserves as we progressed towards our commercialization milestones. Our results of operations support our work on the following the submission of our De Novo application in June of this year to the FDA,” stated J. Michael DiMaio, MD, Chairman of the Board at Spectral AI. “We continue to focus towards bringing this innovative diagnostic device to market in the U.S. to provide clinicians with an immediate, AI trained, data driven assessment tool designed to assist clinical decision-making which may significantly improve patient outcomes.”

SELECT BUSINESS HIGHLIGHTS

Recent Corporate Developments
On October 22, 2025, following the close of the third quarter of 2025, the Company entered into a securities purchase agreement (the “Purchase Agreement”) for the sale of 3,065,000 shares of the Company’s common stock at an offering price of $1.90 per share (such transaction, the “Offering”) and completed a concurrent private placement pursuant to the Purchase Agreement (the “Private Placement”), in which the Company agreed to sell (i) warrants to purchase up to 4,000,000 shares of our common stock, and (ii) pre-funded warrants to purchase up to 935,000 shares of our common stock. The aggregate gross proceeds to the Company from the completion of the Offering and the Private Placement was approximately $7.6 million. The financial statements presented below do not include the effect of this transaction on the Company’s balance sheet.

Q3 2025 FINANCIAL RESULTS OVERVIEW
All comparisons are to the three months ended September 30, 2024 (“Q3 2024”) unless otherwise stated.

Research & Development Revenue
Research & Development Revenue for Q3 2025 declined 54% to $3.8 million from $8.2 million, reflecting the anticipated reduction in direct labor, clinical trial and other reimbursed study costs in connection with the Company’s contract with BARDA (the “BARDA PBS Contract”) following the submission of our De Novo FDA submission in June 2025.

Gross Margin
Gross margin for Q3 2025 was 42.7%, slightly down from 44.9% in Q3 2024, reflecting the reduction in direct labor, clinical trial, and other reimbursed study costs in connection with the Company’s contract with BARDA PBS Contract.

General & Administrative Expense
General and administrative expenses in Q3 2025 were $5.0 million, up from $4.6 million in Q3 2024, reflecting increased consultant and third-party service provider costs from Q3 2024.

Other Income/(Expense)

Other income/(expense) in Q3 2025 was $(0.2) million as compared to $(0.6) million in Q3 2024 primarily relating to the Company’s reduction in its borrowing related costs of almost $0.9 million from Q3 2024.

Net Income/(Loss)
The Company reported a net loss for Q3 2025 of $(3.6) million, compared to a net loss of $(1.5) million in Q3 2024, primarily due to the reduction in revenue as noted above.  

Financial Condition
As of September 30, 2025, cash improved to $10.5 million from $3.7 million in Q3 2024. In addition, the Company’s cash position has remained flat at $10.5 million from Q2 2025. The Company has continued to closely manage its operating costs and has received approximately $2.5 million from stock option and warrant exercises in Q3 2025.

2025 Guidance
The Company has reduced its revenue guidance from $21.5 million to $18.5 million for FY 2025. The reduction reflects timing of work on the BARDA contract and some impact from the current US government shutdown, much of which shall be recaptured in FY 2026. Financial guidance for FY 2025 does not reflect any contributions from the sale of the DeepView™ System for the burn indication or any additional material financial contributions that may result from the commercialization of our DeepView™ System.

CONFERENCE CALL
The Company will host a conference call today at 5:00 pm Eastern Time to discuss these results. Investors interested in participating in the live call can dial:

833-630-1956 – U.S.
412-317-1837 – International

A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company’s website at https://investors.spectral-ai.com/news-events/events.

About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown^®” with its DeepView^® System. The DeepView^® System is being developed as a predictive device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView^® System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView^® System, visit www.spectral-ai.com.

Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.

Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

For Media and Investor Relations, please contact:
David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free – U.S. & Canada
(404) 281-8556 Mobile and WhatsApp Email: dk@atlcp.com

Spectral AI, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share data)
		September 30, 2025			September 30, 2024
Assets
Current Assets:
Cash	$	10,495		$	3,702
Accounts receivable, net		990			2,834
Inventory		454			443
Prepaid expenses		706			1,506
Other current assets		818			1,011
Total current assets		13,463			9,496
Non-current assets:
Property and equipment, net		287			5
Right-of-use assets		1,550			2,101
Total Assets	$	15,300		$	11,602
Liabilities and Stockholders’ Deficit
Current liabilities:
Accounts payable	$	2,538		$	2,797
Accrued expenses		2,475			3,253
Deferred revenue		239			731
Lease liabilities, short-term		713			212
Notes payable, current		1,214			597
Notes payable – at fair value		-			4,377
Warrant liabilities		8,586			1,101
Total current liabilities		15,765			13,068
Note payable – related party		-			1,000
Note payable, long-term		6,581			-
Lease liabilities, long-term		1,157			1,870
Total Liabilities		23,503			15,938
Stockholders’ Deficit
Preferred stock ($0.0001 par value); 1,000,000 shares authorized; no shares issued and outstanding as of September 30, 2025 and September 30, 2024
Common stock ($0.0001 par value); 80,000,000 shares authorized; 27,251,054 and 18,513,073 shares issued and outstanding as of September 30, 2025 and September 30, 2024, respectively		3			2
Additional paid-in capital		48,607			35,998
Accumulated other comprehensive income		39			25
Accumulated deficit		(56,852	)		(40,361	)
Total Stockholders’ Deficit		(8,203	)		(4,336	)
Total Liabilities and Stockholders’ Deficit	$	15,300		$	11,602

SpectralAI, Inc. Condensed Consolidated Statements of Operations (in thousands)
		Three Months Ended						Nine Months Ended
		September 30, 2025			September 30, 2024			September 30, 2025			September 30, 2024
Research and development revenue	$	3,792		$	8,173		$	15,564		$	21,977
Cost of revenue		(2,171	)		(4,506	)		(8,485	)		(12,051	)
Gross profit		1,621			3,667			7,079			9,926
Operating costs and expenses:
General and administrative		4,962			4,553			13,439			15,397
Total operating costs and expenses		4,962			4,553			13,439			15,397
Operating loss		(3,341	)		(886	)		(6,360	)		(5,471	)
Other income (expense):
Net interest expense		(300	)		(8	)		(597	)		-
Borrowing related costs		(164	)		(1,059	)		(869	)		(2,034	)
Change in fair value of warrant liability		264			350			(932	)		718
Change in fair value of notes payable		-			94			220			(7	)
Foreign exchange transaction loss, net		(9	)		(9	)		(31	)		(34	)
Other income (expenses), including transaction costs		-			51			0			(617	)
Total other expense, net		(209	)		(581	)		(2,209	)		(1,974	)
Loss before income taxes		(3,550	)		(1,467	)		(8,569	)		(7,445	)
Income tax provision		(2	)		(37	)		(54	)		(128	)
Net loss	$	(3,552	)	$	(1,504	)	$	(8,623	)	$	(7,573	)
Net loss per share of common stock – basic and diluted	$	(0.13	)	$	(0.08	)	$	(0.34	)	$	(0.44	)
Weighted average common shares outstanding – basic and diluted		26,318,624			17,862,240			25,147,179			17,342,203

Spectral AI, Inc. Unaudited Condensed Consolidated Statements of Cash Flows (in thousands, except share and per share data)
		Nine Months Ended
		September 30, 2025						September 30, 2024
Cash flows from operating activities:
Net loss	$		(8,623	)			$	(7,573	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense			42				6
Amortization of debt issuance costs			283				-
Stock-based compensation			872				858
Amortization of right-of-use assets		421						448
Change in fair value of warrant liabilities		932						(718	)
Change in fair value of notes payable		(220			)			7
Costs from issuance of common stock		-						372
Issuance of shares for borrowing related costs		241						280
Accounts receivable		1,515						(488	)
Inventory		(29			)			(213	)
Prepaid expenses		583						542
Other assets		(72			)			(208	)
Accounts payable		(1,497			)			188
Accrued expenses		(735			)			(1,047	)
Deferred revenue		(721			)			(1,580	)
Lease liabilities		(360			)			(542	)
Net cash used in operating activities		(7,368			)			(9,668	)
Proceeds from issuance of common stock and warrants		3,080						2,667
Proceeds from notes payable		8,260						11,500
Proceeds from notes payable - related party		-						1,000
Payments for notes payable		(1,375			)			(6,600	)
Proceeds from warrant exercises		1,992						-
Stock option exercises		713						-
Net cash provided by financing activities		12,670						8,567
Effect of exchange rates changes on cash		36						13
Net increase/(decrease) in cash		5,338						(1,088	)
Cash, beginning of period		5.157						4,790
Cash, end of period	$	10,495					$	3,702

FAQ

What were Spectral AI (MDAI) Q3 2025 revenues and cash position?

Spectral AI reported Q3 R&D revenue of $3.8M, YTD revenue $15.6M, and cash of $10.5M as of Sept 30, 2025.

Why did Spectral AI (MDAI) R&D revenue fall 54% in Q3 2025?

The decline reflects reduced direct labor, clinical trial, and reimbursed study costs after the company submitted its De Novo FDA submission in June 2025.

How did the Oct 22, 2025 financing affect Spectral AI (MDAI)?

On Oct 22, 2025 the company entered a purchase agreement raising approximately $7.6M gross through common stock, warrants, and pre-funded warrants.

What is Spectral AI (MDAI) guidance for full-year 2025?

Spectral AI reduced FY2025 revenue guidance from $21.5M to $18.5M, citing BARDA timing and U.S. government shutdown impacts.

What was Spectral AI's (MDAI) Q3 2025 net income/(loss)?

The company reported a net loss of $3.6M for Q3 2025 compared with a $1.5M loss in Q3 2024.

Will Spectral AI (MDAI) include the Oct 22, 2025 financing in Q3 financials?

No; the company stated the presented financial statements do not include the effect of the Oct 22, 2025 transaction on the balance sheet.